Rate My Professor Stella Talic

Her research focuses on pharmacoepidemiology, chronic disease prevention and management, therapeutic optimization, medication adherence, patient safety, pharmacoeconomics, and global health. Dr. Talic leads multidisciplinary teams conducting real-world evidence studies, systematic reviews, and pharmacoepidemiological analyses using diverse data sources. Notable publications include “Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset” (2026, Diabetes Technology & Therapeutics), “Adherence patterns to cardiovascular medications in people with type 2 diabetes mellitus: a retrospective cohort study using group-based trajectory analysis in primary care” (2025, Diabetes Research and Clinical Practice), “Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults” (2025, Neurology), “Beta-Blocker Therapy After Myocardial Infarction” (2025, JACC: Advances), and contributions to the Global Burden of Disease Study 2023 (2025, The Lancet). She serves on the Editorial Board of Drugs & Aging and as a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee since 2026. Awards include the John McNeil Early Career Researcher Award for Best Publication in Public Health (2021), School’s Best Research Paper Excellence Award (2021), Early Career Research Excellence Award (2024), and Fellow of the Royal Society for Public Health (2019). With 2628 citations on Google Scholar, her work influences health policy and clinical guidelines, and she mentors students who publish in high-impact journals.